Otonomy, Inc.
6275 Nancy Ridge Drive
Suite 100
San Diego
California
92121
United States
Tel: 858-242-5200
Fax: 858-200-0933
Website: http://www.otonomy.com/
Email: info@otonomy.com
About Otonomy, Inc.
Otonomy is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to address diseases of the inner and middle ear. There are no drugs currently approved by the FDA for the lead indications we are currently pursuing for our product candidates. Our lead candidate AuriPro completed Phase 3 clinical trials in pediatric patients with middle ear effusion at the time of tympanostomy tube placement surgery, and we have submitted a request to the FDA for approval. If approved, we anticipate a commercial launch in early 2016 and are building our business and commercial team to meet the needs of this next stage of our growth.
187 articles about Otonomy, Inc.
-
Otonomy Provides Business Update Related to COVID-19 Pandemic
4/9/2020
Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided a business update related to the COVID-19 pandemic.
-
Otonomy Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
2/27/2020
Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, reported financial results for the fourth quarter and year ended December 31, 2019 and provided an update on its product pipeline and corporate activities.
-
Otonomy to Present at Two Upcoming Investor Conferences
2/24/2020
Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber, Ph.D., president and chief executive officer, is scheduled to present at two upcoming investor conferences:
-
Otonomy to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update
2/20/2020
Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the fourth quarter and full year 2019 as well as provide a corporate update at 4:30 p.m. EST on February 27, 2020.
-
Otonomy Presents Preclinical Results for GJB2 Gene Therapy Collaboration and Cisplatin Otoprotection Program
1/28/2020
Otonomy, Inc. (Nasdaq: OTIC), today announced preclinical results from the company’s gene therapy collaboration with Applied Genetic Technologies Corporation (Nasdaq: AGTC) focused initially on treating GJB2 deficiency for congenital hearing loss, and preclinical results demonstrating the therapeutic potential of a class of compounds being evaluated for otoprotection against cisplatin-induced hearing loss (CIHL).
-
Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual MeetingPreclinical results to be presented for GJB2 gene therapy hearing loss collaboration and OTO-510 program for cisplatin otoprotection
1/23/2020
Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple presentations at the upcoming Association for Research in Otolaryngology (ARO) 43rd Annual MidWinter Meeting, to be held January 25-29, in San Jose, California.
-
Otonomy Provides Corporate and Product Pipeline Update - Jan. 09, 2020
1/9/2020
Three programs with clinical trial results in 2020 including OTIVIDEX™ Phase 3 trial in Ménière’s disease
-
Otonomy Reports Third Quarter 2019 Financial Results and Provides Corporate Update
11/5/2019
Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière’s disease
-
Otonomy to Report Third Quarter 2019 Financial Results and Provide Corporate UpdateWebcast and Conference Call to be Held at 4:30 p.m. EST on November 5, 2019
10/29/2019
Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the third quarter 2019 as well as provide a corporate update at 4:30 p.m. EST on November 5, 2019.
-
Clinical Catch-Up: September 16-20
9/23/2019
Last week was an unusually busy week for clinical trial news, with numerous companies presenting results at conferences. Here’s a look at the top stories. -
Glenmark Therapeutics Expands Specialty Portfolio with OTIPRIO® Co-Promotion Agreement in the U.S. with Otonomy for Acute Otitis Externa Indication
5/2/2019
Glenmark Therapeutics Inc., USA announced a co-promotion agreement with Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology.
-
Otonomy Presents Data Highlighting Potential of OTO-413, an Otic Sustained-Exposure Formulation of BDNF, to Treat Hearing Loss
11/6/2018
Society for Neuroscience Features OTO-413 Presentation as Neuroscience 2018 Hot Topic
-
Otonomy Provides Corporate and Product Pipeline Update - Jan. 9, 2018
1/9/2018
The company provided an update on its product pipeline and financial guidance today.
-
Otonomy said dropping the program and terminating the employees will provide a cash savings of more than $20M in 2018.
-
The company plans to meet with FDA to discuss results and clinical requirements for registration.
-
Otonomy Reports Third Quarter 2017 Financial Results and Provides Corporate Update
11/9/2017
Conference call and webcast today at 4:30 p.m. EST
-
Otonomy Slashes 33% of Staff After Failed Phase III Clinical Trial for Meniere’s Disease
9/14/2017
-
Otonomy Suspends Development of Lead Drug After Phase III Flop, Stock Plunges
8/31/2017
-
Otonomy Reports Second Quarter 2017 Financial Results And Provides Corporate Update
8/4/2017
-
Otonomy To Report Second Quarter 2017 Financial Results And Provide Corporate Update
7/27/2017